The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CODX | -66.96% | -96.84% | -49.86% | -94% |
| S&P | +11% | +85.61% | +13.15% | +170% |
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
Investors continued to avoid the company after its big second-quarter whiffs.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.15M | -29.7% |
| Gross Profit | -$0.15M | 66.4% |
| Gross Margin | -102.00% | 111.5% |
| Market Cap | $16.56M | -58.5% |
| Market Cap / Employee | $0.13M | 0.0% |
| Employees | 132 | -14.8% |
| Net Income | -$5.89M | 39.3% |
| EBITDA | -$6.75M | 34.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.44M | 6.0% |
| Accounts Receivable | $0.06M | -68.6% |
| Inventory | 1.1 | -13.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.73M | -50.6% |
| Short Term Debt | $0.74M | -17.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.95% | -9.4% |
| Return On Invested Capital | -5.86% | 57.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.98M | 19.2% |
| Operating Free Cash Flow | -$5.90M | 18.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.38 | 0.19 | 0.20 | 0.30 | -51.64% |
| Price to Sales | 32.19 | 17.48 | 16.29 | 25.66 | 181.15% |
| Price to Tangible Book Value | 0.64 | 0.36 | 0.43 | 0.83 | -22.01% |
| Enterprise Value to EBITDA | 0.24 | 1.16 | 0.31 | -0.45 | 65.84% |
| Return on Equity | -53.6% | -56.8% | -63.4% | -62.1% | 22.84% |
| Total Debt | $2.15M | $1.93M | $1.70M | $1.47M | -37.86% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
